$VCNX Income Statement | Understand Stock

$VCNX

$0.75 -$0.25 (25.0%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue
Grant revenue
Costs and expenses:
Cost of revenue
Research and development
General and administrative
Total costs and expenses

Loss from operations
Interest expense
Loss on settlement of warrants
Gain on forgiveness of PPP loan
Financing costs - warrant liabilities
Change in fair value of warrant liabilities
Change in fair value of derivative asset
Other income (expense), net
Loss before provision for income taxes
Provision for income taxes
Net loss attributable to noncontrolling interests
Net loss attributable to Vaccinex, Inc. common stockholders
Comprehensive loss
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic
Net loss per share attributable to Vaccinex, Inc. common stockholders, diluted
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic
Weighted-average shares used in computing net loss per share attributable toVaccinex, Inc. common stockholders, diluted

Comments